Is there an any role of neuropeptide Y in the etiology of vitiligo?;Vitiligo etyolojisinde nöropeptid Y'nin rolü var mi?

Turkderm Deri Hastaliklari ve Frengi Arsivi

Volumn 39, Issue 1, 2005, Pages 41-45

  Yayli, Savaş ^a   Bahadir, Sevgi ^a   Deǧer, Orhan ^a   Cimşit, Gülseren ^a   Alpay, Köksal ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Neuropeptide Y; Vitiligo

Indexed keywords

NEUROPEPTIDE Y;

CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; PROTEIN BLOOD LEVEL; VITILIGO;

EID: 26244447843     PISSN: 1019214X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Mosher DB, Fitzpatrick TB, Ortonne JP, Hori Y: Vitiligo. Dermatology in General Medicine, Vol 1.(Ed.) Fitzpatrick TB, Freedberg IM, Eisen, Wolff K. 5th ed. New York, McGraw-Hill, 1999; 949-960.
2. Odom RB, James WD, Berger TG: Andrews' Diseases of the Skin, 9th ed., Philadelphia, W.B. Saunders Company, 2000; 1057-1068.
3. Lerner A: Vitiligo. J Invest Dermatol 1959;32:285-310.
4. Orecchia G: Neural Pathogenesis. Vitiligo. (Ed.) Hann SK, Nordlund JJ. Oxford, Blackwell Science, 2000; 142-150.
5. Palmiter RD, Erickson JC, Hollopeter G, Baraban SC, Schwartz MW: Life without neuropeptide Y. Recent Prog Horm Res 1998;53:163-199.
6. Friedman EM, Irwin MR: Modulation of immune cell function by the autonomic nervous system. Pharmacol Ther 1997;74:27-38.
7. Levite M: Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype (T helper cells 1 and 2). Proc Natl Aced Sci USA 1998;95:12544-12549.
8. Abdel-Naser MB, Krasagakis KS, Krasagakis K, Gollnick H: Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Res 1994;7:1-8.
9. Schwarz H, Villiger PM, von Kempis J, Lotz M: Neuropeptide Y is an inducable gene in the human immune system. J Neuroimmunol 1994;51:53-61.
10. Al'Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ: Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994;131:160-165.
11. Liu PY, Bondesson L, Löntz W, Johansson O: The occurance of cutaneous nerve endings and neuropeptides in vitiligo vulgaris: a case-control study. Arch Dermatol Res 1996;288:670-675.
12. Lazarova R, Hristakieva E, Lazarov N, Shani J: Vitiligo-related neuropeptides in nerve fibers of the skin. Arch Physiol Biochem 2000;108:262-267.
13. Falabella R, Barona MI, Echeverri IC, Alzate A: Subtance P may play a part during depigmentation in vitiligo. A pilot study. J Eur Acad Dermatol Venereol 2003;17:355.
14. Caixia T, Daming Z, Xiran L: Levels of neuropeptide Y in the plasma and skin tissue fluids of patients with vitiligo. J Dermatol Sci 2001;27:178-182.
15. Misery L: Neuro-immuno-cutaneous system. Pathol Biol 1996;44(10):867-874.
16. Hara M, Toyada M, Yaar M, Bhawan J: Innervation of melanocytes in human skin. J Exp Med 1996;184:1385-1395.
17. Hernanz A, Tato E, De la Fuente M, De Miguel E: Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1β, interleukin-6 and tumor necrosis factor-α production by whole blood cells from healhty young and old subjects. J Neuroimmunol 1996;71:25-30.
18. Krasagakis K, Garbe C, Zouboulis CC, Orfanos CE: Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res 1995;139:169-182.
19. Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ: Interleukin 1-β and 6 and tumor necrosis factor-α are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 1991;96:180-185.